Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement
NCT07369089 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88
Last updated 2026-02-03
Summary
The goal of this clinical trial is to examine the usefulness of Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy (KetaMORE) for individuals with opioid use disorder who are receiving medication treatment. The main question it aims to answer is whether individuals with opioid use disorder who receive Mindfulness-Oriented Recovery Enhancement in combination with Ketamine-Assisted Psychotherapy will demonstrate greater reductions in opioid use and craving than individuals who receive Ketamine-Assisted Psychotherapy with a non-mindfulness support group.
Participants will be randomly assigned to receive either Mindfulness-Oriented Recovery Enhancement combined with Ketamine-Assisted Psychotherapy or Ketamine-Assisted Psychotherapy combined with a support group control condition. Researchers will compare these groups on days of opioid use, time to first opioid use lapse, craving, and mood, assessed using ecological momentary assessments and standardized measures collected during treatment and follow-up.
Conditions
Interventions
- DRUG
-
Ketamine will be administered as part of ketamine-assisted psychotherapy under medical supervision according to the study protocol. Ketamine dosing and administration procedures will be identical across study arms.
- BEHAVIORAL
-
Mindfulness-Oriented Recovery Enhancement (MORE)
Mindfulness-Oriented Recovery Enhancement is a manualized, evidence-based intervention integrating mindfulness practices, cognitive reappraisal, and savoring exercises to reduce craving, improve emotional regulation, and support recovery from opioid use disorder. MORE sessions are delivered in a group format and coordinated with ketamine-assisted psychotherapy sessions.
- BEHAVIORAL
-
Support Group
The support group intervention consists of therapist-led group sessions focused on emotional support and discussion of recovery-related experiences. This condition is designed to match the MORE intervention in duration and therapist contact while excluding mindfulness-based or structured skills training.
Sponsors & Collaborators
- collaborator OTHER
-
University of California, San Diego
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-02-28
- Primary Completion
- 2028-01-31
- Completion
- 2028-04-30
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Ketamine for Opioid Use Disorder
NCT06943859 ·Status: RECRUITING ·Phase: PHASE2
-
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.
NCT05995873 ·Status: UNKNOWN ·Phase: NA
-
Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder
NCT06642181 ·Status: RECRUITING ·Phase: PHASE1
-
Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder
NCT04495673 ·Status: TERMINATED ·Phase: NA
-
Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment (R33 Phase)
NCT04278586 ·Status: COMPLETED ·Phase: NA
-
Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder
NCT05042388 ·Status: COMPLETED ·Phase: NA
-
Evaluation of a Physical Device for Medical Use (ADTPM 1) for Opioid Withdrawal Symptoms
NCT07079215 ·Status: RECRUITING ·Phase: NA
-
Cannabidiol in the Treatment of Opioid Use Disorder
NCT06206291 ·Status: COMPLETED ·Phase: PHASE2
-
Adjunctive Bright Light Therapy for Opioid Use Disorder
NCT05459922 ·Status: COMPLETED ·Phase: NA
-
Informational App Development for mHealth for Patient Self-Management of Opioid Use Disorder
NCT05859035 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
NCT04982029 ·Status: COMPLETED ·Phase: PHASE2
-
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
NCT00577408 ·Status: COMPLETED ·Phase: PHASE3
-
Improving Insomnia in Patients With Opioid Use Disorder
NCT05588726 ·Status: WITHDRAWN ·Phase: NA
-
Ketamine for the Treatment of Opioid Use Disorder and Depression
NCT04177706 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders
NCT04340622 ·Status: COMPLETED ·Phase: NA
-
Low-dose Buprenorphine Initiation for Opioid Use Disorder
NCT05450718 ·Status: RECRUITING ·Phase: PHASE4
-
Ketamine for OUD and Suicidal Ideation in the ED
NCT06111339 ·Status: TERMINATED ·Phase: PHASE2
-
Enhancing Exercise and Psychotherapy to Treat Pain and Addiction in Adults With an Opioid Use Disorder (EXPO; R33 Phase)
NCT05688410 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder
NCT02044094 ·Status: COMPLETED ·Phase: PHASE2
-
OMAR Opioid Use Disorder
NCT05683184 ·Status: RECRUITING ·Phase: PHASE1
-
Study for Naltrexone on the Abuse Potential of Methylphenidate
NCT03769064 ·Status: COMPLETED ·Phase: PHASE1
-
Scheduled Intranasal Ketamine
NCT05671913 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Neurobehavioral Mechanisms of Choice in Opioid Use Disorder
NCT03958474 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
NCT06086275 ·Status: COMPLETED ·Phase: PHASE1
-
Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1
NCT00238914 ·Status: COMPLETED ·Phase: PHASE2